Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits
Beatrice Lupsa, Silvio E. Inzucchi
Diabetologia (2018) Vol. 61, Iss. 10, pp. 2118-2125
Open Access | Times Cited: 167

Showing 1-25 of 167 citing articles:

From NASH to diabetes and from diabetes to NASH: Mechanisms and treatment options
Amalia Gastaldelli, Kenneth Cusi
JHEP Reports (2019) Vol. 1, Iss. 4, pp. 312-328
Open Access | Times Cited: 351
Sodium–glucose cotransporter type 2 inhibitors for the treatment of type 2 diabetes mellitus
André Scheen
Nature Reviews Endocrinology (2020) Vol. 16, Iss. 10, pp. 556-577
Closed Access | Times Cited: 228
Trends in Antidiabetic Drug Discovery: FDA Approved Drugs, New Drugs in Clinical Trials and Global Sales
Amelia D. Dahlén, Giovanna Dashi, Ivan Maslov, et al.
Frontiers in Pharmacology (2022) Vol. 12
Open Access | Times Cited: 173
SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA
Pantelis Sarafidis, Charles J. Ferro, Enrique Morales, et al.
Nephrology Dialysis Transplantation (2019) Vol. 34, Iss. 2, pp. 208-230
Open Access | Times Cited: 172
Dapagliflozin: A Review in Type 2 Diabetes
Sohita Dhillon
Drugs (2019) Vol. 79, Iss. 10, pp. 1135-1146
Open Access | Times Cited: 165
European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose‐lowering drugs in patients with heart failure
Petar Seferović, Andrew J.S. Coats, Piotr Ponikowski, et al.
European Journal of Heart Failure (2019) Vol. 22, Iss. 2, pp. 196-213
Open Access | Times Cited: 156
An update on the safety of SGLT2 inhibitors
André Scheen
Expert Opinion on Drug Safety (2019) Vol. 18, Iss. 4, pp. 295-311
Closed Access | Times Cited: 155
Recent Developments in Biomarkers for Diagnosis and Screening of Type 2 Diabetes Mellitus
Margarita Ortiz‐Martínez, Mirna González‐González, Alexandro J. Martagón, et al.
Current Diabetes Reports (2022) Vol. 22, Iss. 3, pp. 95-115
Open Access | Times Cited: 110
Diabetic kidney disease: New clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on “The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function”
Giuseppe Pugliese, Giuseppe Penno, Andrea Natali, et al.
Nutrition Metabolism and Cardiovascular Diseases (2019) Vol. 29, Iss. 11, pp. 1127-1150
Open Access | Times Cited: 141
Empagliflozin reduces the levels of CD36 and cardiotoxic lipids while improving autophagy in the hearts of Zucker diabetic fatty rats
Alana Aragón‐Herrera, Sandra Feijóo‐Bandín, Manuel Otero Santiago, et al.
Biochemical Pharmacology (2019) Vol. 170, pp. 113677-113677
Closed Access | Times Cited: 140
Anti-Obesity Drugs: Long-Term Efficacy and Safety: An Updated Review
Young Jin Tak, Sang Yeoup Lee
The World Journal of Men s Health (2020) Vol. 39, Iss. 2, pp. 208-208
Open Access | Times Cited: 130
Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes
Guntram Schernthaner, Naim Shehadeh, Ametov As, et al.
Cardiovascular Diabetology (2020) Vol. 19, Iss. 1
Open Access | Times Cited: 127
An update on therapies for the treatment of diabetes-induced osteoporosis
Sahar Mohsin, May M.Y.H. Baniyas, Reem SMH AlDarmaki, et al.
Expert Opinion on Biological Therapy (2019) Vol. 19, Iss. 9, pp. 937-948
Closed Access | Times Cited: 111
Diabetic kidney disease: new clinical and therapeutic issues. Joint position statement of the Italian Diabetes Society and the Italian Society of Nephrology on “The natural history of diabetic kidney disease and treatment of hyperglycemia in patients with type 2 diabetes and impaired renal function”
Giuseppe Pugliese, Giuseppe Penno, Andrea Natali, et al.
Journal of Nephrology (2019) Vol. 33, Iss. 1, pp. 9-35
Open Access | Times Cited: 103
SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline
Sheyu Li, Per Olav Vandvik, Lyubov Lytvyn, et al.
BMJ (2021), pp. n1091-n1091
Open Access | Times Cited: 90
Unlocking the Full Potential of SGLT2 Inhibitors: Expanding Applications beyond Glycemic Control
Mahmoud E. Youssef, Galal Yahya, Mihaela Simona Popoviciu, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6039-6039
Open Access | Times Cited: 37
Pharmacological Support for the Treatment of Obesity—Present and Future
Marcin Kosmalski, Kacper Deska, Bartłomiej Bąk, et al.
Healthcare (2023) Vol. 11, Iss. 3, pp. 433-433
Open Access | Times Cited: 24
The effect of sodium glucose Co-transport 2 inhibitors on cognitive impairment and depression in type 2 diabetes mellitus patients
Ashurova Nodirahon, Haya Majid, Swati Waghdhare, et al.
Clinical Epidemiology and Global Health (2024) Vol. 26, pp. 101555-101555
Open Access | Times Cited: 10
Effect of Drugs Used in Pharmacotherapy of Type 2 Diabetes on Bone Density and Risk of Bone Fractures
Agnieszka Wikarek, Małgorzata Grabarczyk, Katarzyna Klimek, et al.
Medicina (2024) Vol. 60, Iss. 3, pp. 393-393
Open Access | Times Cited: 9
Diabetes mellitus in patients with acromegaly: pathophysiology, clinical challenges and management
Daniela Espósito, César Luiz Boguszewski, Annamaria Colao, et al.
Nature Reviews Endocrinology (2024) Vol. 20, Iss. 9, pp. 541-552
Closed Access | Times Cited: 9
Bone health in diabetes and prediabetes
Silvia Costantini, Caterina Conte
World Journal of Diabetes (2019) Vol. 10, Iss. 8, pp. 421-445
Open Access | Times Cited: 69
Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19
Sang Youl Rhee, Jeong-Woo Lee, Hyewon Nam, et al.
Diabetes & Metabolism Journal (2021) Vol. 45, Iss. 2, pp. 251-259
Open Access | Times Cited: 54
Effects of SGLT2 Inhibitors on Ion Homeostasis and Oxidative Stress associated Mechanisms in Heart Failure
Gloria M. Gager, Dirk von Lewinski, Harald Sourij, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 143, pp. 112169-112169
Open Access | Times Cited: 44
Glucose variability and diabetes complications: Risk factor or biomarker? Can we disentangle the “Gordian Knot”?
L. Monnier, C Colette, David R. Owens
Diabetes & Metabolism (2021) Vol. 47, Iss. 3, pp. 101225-101225
Open Access | Times Cited: 42
Safety and efficacy of the SGLT2 inhibitor dapagliflozin in patients with systemic lupus erythematosus: a phase I/II trial
Huijing Wang, Ting Li, Fangfang Sun, et al.
RMD Open (2022) Vol. 8, Iss. 2, pp. e002686-e002686
Open Access | Times Cited: 29
Page 1 - Next Page

Scroll to top